BIMZELX
Google image searchProduct monograph
Active ingredient
bimekizumab, 160 MG/ML
DIN: 02525275
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: AUTOINJECTOR
Schedule: Prescription / Schedule D
Company: UCB CANADA INC
Date: 30-MAR-2022
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC21 — BIMEKIZUMAB (ATC/DDD)
